Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?
Amarin’s fish oil formulation Vascepa impressed on hard cardiovascular endpoints, but there is confusion about worsening cholesterol in the placebo group.
Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap…
The topline result from Amarin’s Reduce-It trial has smashed expectations, delighting shareholders and framing Vascepa as a potentially practice-changing product.
The Ascend trial failure is a blow to the fish oil theory, but Amarin insists that it does not bode ill for its big readout.
Featuring at the European Society of Cardiology meeting, which kicks off this weekend in Munich, are results with tafamidis, Xarelto and fish oil supplements.
Amarin's huge cardiovascular outcomes study of Vascepa will read out soon, but an emphatic victory looks unlikely.